KIORA PHARMACEUTICALS INC — Director's Dealing 2021

Nov 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EYEGATE PHARMACEUTICALS INC (EYEG)
CIK: 0001372514
Period of Report: 2021-11-02

Reporting Person: Mann Brenda (VP of Research & Development)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-02	Common Stock	F	62	$1.98	Disposed	15136	Direct

Footnotes

F1: Sale of shares to cover taxes due on restricted stock that vested on 11/01/2021.